Clinical Trials for Endocrine Cancers

3 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TherapeuticCOGADVL1121
06/13/2012
ADVL1121 - A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
TherapeuticVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
Screen, Detect, DiagnoseVICCMD1286
12/17/2012
Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib

You do not have JavaScript enabled. This site works better with JavaScript turned on.